Refractory or Recurrent Solid Tumors
1 competing product in clinical development for Refractory or Recurrent Solid Tumors.
Pipeline by Phase
Phase 1/21
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Eribulin mesilate + Irinotecan hydrochloride | Eisai | Phase 1/2 | Completed | 32 |